Overview Monte Rosa is looking for an experienced Program and Alliance Manager with research and early clinical development experience in biotech to oversee internal and partnered programs. Leveraging their drug development, project management and cross-functional team
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Postdoctoral Fellow - Cancer Immunology (100%) University of Basel ranks among the world’s one hundred best universities and boasts a top‑ten place among German‑speaking universities. The Department of Biomedicine is a joint effort between the University